Navigation Links
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma

Oral presentation at international lymphoma conference shows investigational regimen resulted in 82 percent overall survival and 78

percent progression-free survival rates in patients receiving

radioimmunotherapy Confirmatory phase III clinical trial is presently being conducted in this

patient population

LUGANO, Switzerland, June 9 /PRNewswire-FirstCall/ -- In an oral presentation today at the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland, Paul A. Hamlin, M.D., of Memorial Sloan-Kettering Cancer Center, presented results of an investigator-sponsored trial of the investigational regimen consolidating rituximab-CHOP (R-CHOP) with 90Yttrium Ibritumomab Tiuxetan (Zevalin(R)) radioimmunotherapy in high risk, elderly patients with previously untreated high-intermediate and high risk diffuse large B-cell lymphoma (DLBCL). Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) markets Zevalin in the United States.

"In a high risk, elderly patient population with significant comorbidities, sequential R-CHOP followed by radioimmunotherapy resulted in excellent complete response and overall and progression-free survival rates," concluded Hamlin. "This approach is now the focus of an international phase III study."

"Improvement of relapse-free survival in these patients is an important unmet need since the outcome is poor for patients who relapse with this disease and who cannot tolerate intensive salvage therapy and stem cell transplantation," said Jack W. Singer, M.D., Chief Medical Officer at CTI. "The survival data from this study are highly encouraging compared to historical data and provide the rationale for a registration-directed randomized trial of Zevalin consolidation in higher risk patients with DLBCL."

Results of the Study

Historical studies provided as background in the presentation indicate that approximately 50 percent of elderly patients with high risk diffuse large B-cell lymphoma (DLBCL) relapse after treatment with R-CHOP. Treatment options for patients who are ineligible for autologous stem cell transplant are limited. In this analysis, of the 63 patients enrolled on the study, 39 patients had been treated with Zevalin. The median age is 75 years (range 62-86); Karnofsky performance status was <80 percent in 59 percent of patients with a median performance status of 70 percent; prognostic score was high-intermediate/high in 53 percent and 47 percent of patients, respectively. Moderate or high impact comorbidity is present in 86 percent. In the intent-to-treat population, progression-free (PFS) and overall survival (OS) were 59 percent and 65 percent, respectively, at 22 months. In the 39 patients who received Zevalin, PFS and OS were 78 percent and 82 percent, respectively, at 26 months. Responses improved in 11 patients who received Zevalin, with eight patients improving from an unconfirmed (CRu) to a confirmed complete response (CR) and three patients improving from a partial response (PR) to a CR/CRu. The side effects reported included blood count suppression: 26 percent and 36 percent grade 3/4 neutropenia, 15 percent grade 3 anemia, and 36 percent and 31 percent grade 3/4 thrombocytopenia. Six patients had delayed blood count recovery for more than 12 weeks. One patient developed myelodysplasia and two patients died after Zevalin was given, one from a suspected brain hemorrhage and one from congestive heart failure.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit for more information.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products. For additional information, please visit

Sign up for email alerts and get RSS feeds at our Web site,

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential failure of Zevalin to prove safe and effective for treatment of high risk elderly DLBCL, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling Zevalin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200


Investors Contact:

Ed Bell

T: 206.282.7100

F: 206.272.4434


Medical Information Contact:

T: 800.715.0944


SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
2. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
6. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
7. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
8. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
9. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
(Date:11/25/2015)... , Nov. 25, 2015  ARKRAY ... products, continues to provide evidence demonstrating the accuracy of ... World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease ... that both the Company,s GLUCOCARD ® 01 meter ... high accuracy requirements. The ability to accurately measure glucose ...
(Date:11/25/2015)... , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused on ... of various clinical conditions, today announced the closing of ... Depository Shares ( ADSs ), each representing 20 ordinary ... to 3,158,900 ADSs. The ADSs and warrants were issued ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and women ... healthcare organizations in the country. They have overseen financial turnarounds, shown commitment to ... the healthcare industry as a whole through their advocacy and professional efforts. , ...
(Date:11/26/2015)... ... 2015 , ... Inevitably when people think Thanksgiving, they also think Holiday sales ... Black Friday and Cyber Monday massage chair sales to receive the best ... low to find the best massage chair deals, they can see all of the ...
(Date:11/26/2015)... ... ... PRMA Plastic Surgery is updating their record books yet again with an ... breast reconstruction surgery! , “What an accomplishment for the PRMA team, says Dr. ... an honor to have served all of these women.” , PRMA is one of ...
Breaking Medicine News(10 mins):